{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:05:30Z","timestamp":1782633930362,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015631","name":"Merck Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jogc.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jogc.2025.102783","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T16:56:48Z","timestamp":1738342608000},"page":"102783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["What Are the Current HPV Types Contributing to Cervical High-Grade Squamous Intraepithelial Lesions, Adenocarcinoma In Situ, and Early Cervical Cancer?"],"prefix":"10.1016","volume":"47","author":[{"given":"Lina","family":"Salman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian T.","family":"Gien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Vicus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kupets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Ashfaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Severini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Covens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.jogc.2025.102783_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1201-9712(07)60015-0","article-title":"Human papillomavirus infection and the development of cervical cancer and related genital neoplasias","volume":"11","author":"Paavonen","year":"2007","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jogc.2025.102783_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jogc.2025.102783_bib3","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2025.102783_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/TCRM.S856","article-title":"A\u00a0novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil)","volume":"4","author":"Govan","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jogc.2025.102783_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/vaccines8030391","article-title":"Human papillomavirus vaccines: an updated review","volume":"8","author":"Cheng","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jogc.2025.102783_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.57.1.7","article-title":"American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jogc.2025.102783_bib7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jama.2019.18411","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"323","author":"Oshman","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2025.102783_bib8","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2025.102783_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.vaccine.2012.10.092","article-title":"Impact of human papillomavirus (HPV) vaccination on HPV 16\/18-related prevalence in precancerous cervical lesions","volume":"31","author":"Powell","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jogc.2025.102783_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.vaccine.2013.10.085","article-title":"Reduction in HPV 16\/18 prevalence in sexually active young women following the introduction of HPV immunisation in England","volume":"32","author":"Mesher","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jogc.2025.102783_bib11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/JCM.06090-11","article-title":"Novel microsphere-based method for detection and typing of 46 mucosal human papillomavirus types","volume":"50","author":"Zubach","year":"2012","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jogc.2025.102783_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106641","article-title":"The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts","volume":"150","author":"Clark","year":"2021","journal-title":"Prev Med"},{"key":"10.1016\/j.jogc.2025.102783_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2025.102783_bib14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/21645515.2020.1839292","article-title":"Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up","volume":"17","author":"Kjaer","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jogc.2025.102783_bib15","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.1016\/j.vaccine.2020.07.037","article-title":"HPV16\/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination","volume":"38","author":"Cornall","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jogc.2025.102783_bib16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jogc.2025.102783_bib17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3892\/etm.2020.9316","article-title":"Non-sexual HPV transmission and role of vaccination for a better future review","volume":"20","author":"Petca","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jogc.2025.102783_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2021.01.020","article-title":"High-risk HPV-positive and -negative high-grade cervical dysplasia: analysis of 5-year outcomes","volume":"161","author":"Bogani","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2025.102783_bib19","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1002\/ijc.30032","article-title":"Evaluating HPV-negative CIN2+ in the ATHENA trial","volume":"138","author":"Petry","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jogc.2025.102783_bib20","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.3390\/curroncol29050303","article-title":"HPV vaccination: an underused strategy for the prevention of cancer","volume":"29","author":"Shapiro","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jogc.2025.102783_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106925","article-title":"Corrigendum to \u201cHPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010\u20132019\u201d","volume":"155","author":"Bruni","year":"2022","journal-title":"Prev Med"},{"key":"10.1016\/j.jogc.2025.102783_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ijc.31094","article-title":"What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study","volume":"142","author":"Landy","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jogc.2025.102783_bib23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2017.12.018","article-title":"Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines","volume":"91","author":"Pedersen","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jogc.2025.102783_bib24","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2025.102783_bib25","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2021.01.074","article-title":"Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27\u201345 years of age compared to women 16\u201326 years of age: an open-label phase 3 study","volume":"39","author":"Joura","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jogc.2025.102783_bib26","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216325000234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216325000234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T20:40:10Z","timestamp":1742244010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1701216325000234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1701216325000234"],"URL":"https:\/\/doi.org\/10.1016\/j.jogc.2025.102783","relation":{},"ISSN":["1701-2163"],"issn-type":[{"value":"1701-2163","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Are the Current HPV Types Contributing to Cervical High-Grade Squamous Intraepithelial Lesions, Adenocarcinoma In Situ, and Early Cervical Cancer?","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2025.102783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by ELSEVIER INC. on behalf of The Society of Obstetricians and Gynaecologists of Canada\/La Soci\u00e9t\u00e9 des obst\u00e9triciens et gyn\u00e9cologues du Canada.","name":"copyright","label":"Copyright"}],"article-number":"102783"}}